Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Dose Escalation Safety and Efficacy Trial of DE-112 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension

NCT01279083 is registered in ClinicalTrials.gov with Santen Inc. as lead sponsor.

NCT NCT01279083
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01279083 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Dose Escalation Safety and Efficacy Trial of DE-112 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension
Lead sponsor
Santen Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
January 31, 2011
Completion date
February 29, 2012
Enrollment
147 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

ocular hypertension, open-angle glaucoma